Bibiliografía

1. Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37-46. [PubMed]

2. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug 1;3(8):e379-87. [PubMed]

3. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015 Jul;114(1):150-7. [PubMed]

4. Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015 Sep 1;136(3):582-9. [PubMed]

5. Di Minno MND, Ageno W, Lupoli R, Conte G, van Es N, Buller HR, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. Eur Respir J. 2017 Sep 1;50(3). [PubMed]

6. Sobieraj DM, Baker WL, Smith E, Sasiela K, Trexler SE, Kim O, et al. Anticoagulation for the Treatment of Cancer-Associated Thrombosis: a Systematic Review and Network Meta-Analysis of Randomized Trials. Clin Appl Thromb. 2018 Dec 1;24(9_suppl):182S-187S. [PubMed]

7. Vedovati MC, Giustozzi M, Bonitta G, Agnelli G, Becattini C. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: a network meta-analysis. Thromb Res. 2018 Oct 1;170:175-80. [PubMed]

8. Li A, García DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019 Jan 1;173:158-63. [PubMed]

9. Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018 Jun 19;6(6):CD006650. [PubMed]

10. Smith JD, Baillie J, Baglin T, Griffiths GO, Casbard A, Cohen D, et al. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin In the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study. Trials. 2014 Apr 12;15(1). [Enlace]

11. Bott-Kitslaar DM, Saadiq RA, McBane RD, Loprinzi CL, Ashrani AA, Ransone TR, et al. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: a Single-Center Registry. Am J Med. 2016 Jun 1;129(6):615-9. [PubMed]

12. Xavier FD, Hoff PMG, Braghiroli MI, Paterlini ACCR, Souza KT, Faria LDBB, et al. Rivaroxaban: an Affordable and Effective Alternative in Cancer-Related Thrombosis? J Glob Oncol. 2017 Feb;3(1):15-22. [PubMed]

13. Pignataro BS, Nishinari K, Cavalcante RN, Centofanti G, Yazbek G, Krutman M, et al. Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients with Active Cancer: a Single-Center Experience. Clin Appl Thromb. 2017 Oct 1;23(7):883-7. [PubMed]

14. Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, et al. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. Am J Med. 2018 Apr 1;131(4):430-7. [PubMed]

15. Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol. 2018 May 1;93(5):664-71. [PubMed]

16. Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberté F, Crivera C, et al. The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation. Am J Hematol. 2019 Feb;94(2):E58-E61. [PubMed]

17. Mahé I, Plaisance L, Chapelle C, Laporte S, Planquette B, Bertoletti L, et al. Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study. Cancers (Basel). 2020 Aug 12;12(8):2256. [PubMed]

18. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer. Am J Med. 2006 Dec;119(12):1062-72. [PubMed]

19. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN Study. J Thromb Haemost. 2015 Jun 1;13(6):1028-35. [PubMed]

20. Jara-Palomares L, Solier-López A, Elías-Hernández T, Asensio-Cruz M, Blasco-Esquivias I, Marín-Barrera L, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017 Sep 1;157:90-6. [PubMed]

21. Raskob GE, Van Es N, Verhamme P, Carrier M, Di Nisio M, García D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-24. [PubMed]

22. Di Nisio M, van Es N, Carrier M, Wang TF, García D, Segers A, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 Nov 1;17(11):1866-74. [PubMed]

23. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-23. [PubMed]

24. Marshall A, Levine M, Hill C, Hale D, Thirlwall J, Wilkie V, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). J Thromb Haemost. 2020 Apr 1;18(4):905-15. [PubMed]

25. Watson HG, Keeling DM, Laffan M, Tait RC, Makris M. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015 Sep 1;170(5):640-8. [PubMed]

26. Kearon C, Akl EA, Ornelas J, Blaivas A, Jiménez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb 1;149(2):315-52. [PubMed]

27. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN Guidelines® insights cancer-associated venous thromboembolic disease, version 2.2018 featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. 2018 Nov 1;16(11):1289-303. [PubMed]

28. Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018 Sep 1;16(9):1891-4. [PubMed]

29. Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, Ageno W, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. [PubMed]

30. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347. [PubMed]

31. Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. Crit Rev Oncol Hematol. 2018 Dec;132:169-79. [PubMed]

32. Prisco D, Ageno W, Becattini C, D’Angelo A, Davì G, De Cristofaro R, et al. Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med. 2017 Apr 1;12(3):387-406. [PubMed]

33. Napolitano M, Saccullo G, Malato A, Sprini D, Ageno W, Imberti D, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The cancer-DACUS study. J Clin Oncol. 2014 Nov 10;32(32):3607-12. [PubMed]

34. Jara-Palomares L, Solier-López A, Elías-Hernández T, Asensio-Cruz MI, Blasco-Esquivias I, Sánchez-López V, et al. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. Br J Cancer. 2018 Oct 16;119(8):915-21. [PubMed]

35. Raskob GE, Van Es N, Verhamme P, Carrier M, Di Nisio M, García D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-24. [PubMed]

36. Lee AYY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013 Oct 3;122(14):2310-7. [PubMed]

37. Königsbrügge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: Novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res. 2014 May;133 Suppl 2:S39-43. [PubMed]

 

Links de interés